402 related articles for article (PubMed ID: 7554971)
1. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
2. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
3. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
4. Enlarged follicles in women using oral contraceptives.
Broome M; Clayton J; Fotherby K
Contraception; 1995 Jul; 52(1):13-6. PubMed ID: 8521709
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
6. Changes in androgens during treatment with four low-dose contraceptives.
Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
[TBL] [Abstract][Full Text] [Related]
7. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
8. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
van der Does J; Exalto N; Dieben T; Bennink HC
Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
[TBL] [Abstract][Full Text] [Related]
9. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
Norris LA; Bonnar J
Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
[TBL] [Abstract][Full Text] [Related]
10. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
12. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J; Müller U; Düsterberg B
Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
[TBL] [Abstract][Full Text] [Related]
13. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
14. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
15. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
16. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
17. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
18. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
[TBL] [Abstract][Full Text] [Related]
19. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
20. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
